How much cash does Moderna have and is it enough?
Moderna announced a $2.0B convertible notes offering, extending its cash runway to 2–2.5 years. The funds will support oncology pipeline, debt repayment, and dilution management. Revenue has collapsed 99% since FY2022, with Q2 2026 at $145M. Post-raise, cash is estimated at $3.5–3.8B, with a quarterly burn of $600–700M.
How this was made
The 30-second read
Why it matters
Traders can reassess probability-weighted timelines for intismeran milestones versus the risk of needing additional financing before commercialization, with dilution as the key overhang.
Market read
A sizable convertible raise with explicit runway math is a direct, tradable catalyst for MRNA, shifting focus to dilution risk and financing sufficiency for oncology milestones.
What to watch
Investors may underweight the possibility of partnership cost-sharing (Merck) and overemphasize burn rate variability tied to trial timing and milestone payments.
Background
The piece frames Moderna’s liquidity adequacy by combining reported cash, burn rate, and a new convertible notes raise tied to intismeran’s path toward an FDA filing decision.
Ticker impact
Moderna announced a $2.0B convertible notes offering, citing $1.72B cash and a $600M to $700M quarterly burn to extend runway.
Near-term, expect volatility around dilution expectations and runway confidence; direction depends on how investors price the oncology timeline versus conversion overhang.
The article provides concrete financing terms and runway math, but it does not add new clinical or regulatory milestones beyond referencing prior Phase 3 data.
Market effects
Biotech financing conditions and dilution sensitivity may remain elevated, especially for late-stage oncology programs reliant on cash runway.
Limited direct regional spillover; primarily impacts US biotech risk appetite and convertible-debt pricing sentiment.
Moderna’s oncology funding narrative can influence global mRNA/oncology peer sentiment, but the catalyst is company-specific.
Counterpoint
The convertible structure plus capped-call mechanics may be less dilutive than feared if the stock does not sustain strong upside into conversion pricing.
Key entities
- companyModerna
Subject of the article, raising $2.0B to $2.3B via convertible notes to fund oncology pipeline and manage runway.
- productintismeran
Moderna’s mRNA cancer vaccine program referenced as the critical use of proceeds toward a potential launch decision.
- partnerMerck
Referenced as a potential cost-sharing partner for intismeran, which could reduce cash burn needs.
